Publication:
NSAIDs Medication for Headache as the Presenting Symptom with Migraine and COVID-19

dc.authorscopusid57208188167
dc.authorscopusid23062131200
dc.contributor.authorTürkdönmez, E.
dc.contributor.authorTerzi, M.
dc.date.accessioned2025-12-11T00:28:43Z
dc.date.issued2021
dc.departmentOndokuz Mayıs Üniversitesien_US
dc.department-temp[Türkdönmez] Elif, Department of Physiology, Ondokuz Mayis University, Medical School, Samsun, Turkey; [Terzi] Murat, Department of Neurology, Ondokuz Mayis University, Medical School, Samsun, Turkeyen_US
dc.description.abstractHeadache is one of the most prevalent disorders of the nervous system. Headache is also the most common symptom of a variety of diseases, including migraine, COVID-19. International Classification of Headache Disorders (ICHD) lists over a thousand different types of headaches. Migraine is a widely known type of primary headache. Much research supports that the enhancement in migraine intensity related to chronic migraine such as neurogenic neuroinflammation, possibly leading to increased cytokine expression via activation of protein kinases in neurons and glial cells of the trigeminovascular system like some of the other headache diseases. No currently drug class available, either specific (triptans, ergots) or non-specific (opioids, paracetamol, NSAIDs), is effective in all types of headaches, in all patients and all attacks of the same patient. However, non-steroidal anti-inflammatory drugs (NSAIDs) minimize prostaglandin synthesis by blocking cyclooxygenase, which is included in the pathophysiology of migraine headaches. We searched the employed source was The Journal of Headache and Pain database by using NSAIDs with Headache, Migraine, and COVID-19 keywords. The search was performed from April 2021 and included 2017-2018-2019-2020-2021 (last five years) the studies and reviews from the Journal of Headache and Face Pain Sites. Additionally, we noted the published or on-going studies, eight of these, about NSAIDs information contain searches that exist in the 12th European Headache Federation Congress (jointly with 32nd National Congress of the Italian Society) Study of Headaches’ book. Also, we included relationship migraine with COVID-19 studies to highlight the connection between the headache, which is one of the most common symptoms of both migraine and COVID-19, and the importance of managing migraine pain with NSAIDs during corona processing. © 2021 Ondokuz Mayis Universitesi. All rights reserved.en_US
dc.identifier.doi10.52142/OMUJECM.38.4.43
dc.identifier.endpage648en_US
dc.identifier.issn1309-4483
dc.identifier.issn1309-5129
dc.identifier.issue4en_US
dc.identifier.scopus2-s2.0-85122149525
dc.identifier.scopusqualityQ4
dc.identifier.startpage645en_US
dc.identifier.urihttps://doi.org/10.52142/OMUJECM.38.4.43
dc.identifier.urihttps://hdl.handle.net/20.500.12712/36570
dc.identifier.volume38en_US
dc.language.isoenen_US
dc.publisherOndokuz Mayis Universityen_US
dc.relation.ispartofJournal of Experimental and Clinical Medicine (Turkey)en_US
dc.relation.publicationcategoryMakale - Uluslararası Hakemli Dergi - Kurum Öğretim Elemanıen_US
dc.rightsinfo:eu-repo/semantics/closedAccessen_US
dc.subjectHeadacheen_US
dc.subjectMigraineen_US
dc.subjectNeuroinflammationen_US
dc.subjectNon-Steroid Anti-Inflammatory Drugs (NSAIDs)en_US
dc.titleNSAIDs Medication for Headache as the Presenting Symptom with Migraine and COVID-19en_US
dc.typeArticleen_US
dspace.entity.typePublication

Files